PFE is going to pick one of the two agents for phase-3 trials. On today's webcast, PFE said Danuglipron can be formulated as a qD drug if it looks like the better of the two compounds, so dosing frequency won't be the issue that determines which of the two compounds is chosen.
Both PFE compounds can be dosed without regard to food, which PFE sees as a material advantage compared to NVO's Rybelsus, which requires fasting.
Market Data 
Markets 
AI
